The company signed a key deal to market its hepatitis B vaccine in Germany.
News & Analysis: Dynavax Technologies
The company announced the pricing of its senior convertible notes offering.
The biotech announced a senior convertible notes offering.
DVAX earnings call for the period ending March 31, 2021.
The company's hepatitis B vaccine wasn't its key growth driver.
Investors cheered good news from the company's COVID-19 vaccine partner.
The biotech's better-than-expected Q4 update pointed to even better days ahead.
The company's collaborations and CpG 1018 vaccine adjuvant are playing an increasingly important role.
DVAX earnings call for the period ending December 31, 2020.
The company's hepatitis B virus vaccine won European Union approval.